Antibody profile in Indian severe haemophilia A patients with and without FVIII inhibitors

被引:1
作者
Pinto, Patricia [1 ]
Shetty, Shrimati [1 ]
Lacroix-Desmazes, Sebastien [2 ,3 ,4 ,5 ,6 ]
Bayry, Jagadeesh [2 ,3 ,4 ,5 ,6 ]
Kaveri, Srini [2 ,3 ,4 ,5 ,6 ]
Ghosh, Kanjaksha [1 ]
机构
[1] Natl Inst Immunohaematol ICMR, 13th Floor,New Multistoreyed Bldg,KEM Hosp Campus, Bombay 400012, Maharashtra, India
[2] Ctr Rech Cordeliers, INSERM, UMRS 1138, Paris, France
[3] Univ Paris 06, UMRS 1138, Paris, France
[4] Univ Paris 05, UMRS 1138, Paris, France
[5] Lab Int Assoc INSERM, Paris, France
[6] ICMR, Paris, France
关键词
Haemophilia A; FVIII; Inhibitors; Autoantibodies; India; FACTOR-VIII INHIBITORS; PREVIOUSLY UNTREATED PATIENTS; RECOMBINANT FACTOR-VIII; RISK-FACTORS; ACQUIRED HEMOPHILIA; LUPUS ANTICOAGULANT; FACTOR-IX; HEPATITIS-C; EFFICACY; MARKERS;
D O I
10.1016/j.imlet.2015.09.013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Diagnosis and management of haemophilia patients with inhibitors is often tricky due to the heterogeneous nature of the antibodies with regard to their kinetics, as well as the co-existence of other interfering antibodies. Plasma samples from severe haemophilia A patients from India with and without FVIII inhibitors were analysed for the presence of possible co-existing antibodies such as lupus anticoagulants (LA), anti-cardiolipin antibodies (ACLA), anti-132-glycoprotein-I (anti-beta 2-GP-I) antibodies, viral transfusion transmitted disease (HIV, HBsAg, HCV) related antibodies, anti-cyclic citrullinated peptides (anti-CCP), and anti-nuclear antibodies. A high incidence of LA and anti-HCV antibodies was detected in Indian haemophilia A patients similar to earlier reports. More importantly, a relatively high incidence of autoantibodies to nuclear antigens (18.62%) and anti-CCP antibodies (1.38%) associated with autoimmune disorders was also seen in these congenital haemophilia A patients with and without inhibitors. Knowledge on the antibody profile in these haemophilia patients especially in those with FVIII inhibitors along with correlation with the clinical manifestations and other risk factors for inhibitor development could possibly shed more light on the complex immune response in these patients. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:93 / 97
页数:5
相关论文
共 46 条
  • [1] Agarwal N, 2001, INDIAN J MED RES, V113, P170
  • [2] NATURAL ANTIBODIES TO FACTOR-VIII (ANTI-HEMOPHILIC FACTOR) IN HEALTHY-INDIVIDUALS
    ALGIMAN, M
    DIETRICH, G
    NYDEGGER, UE
    BOIELDIEU, D
    SULTAN, Y
    KAZATCHKINE, MD
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (09) : 3795 - 3799
  • [3] Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors
    Astermark, J.
    [J]. HAEMOPHILIA, 2006, 12 : 8 - 13
  • [4] FVIII inhibitors: pathogenesis and avoidance
    Astermark, Jan
    [J]. BLOOD, 2015, 125 (13) : 2045 - 2051
  • [5] Bellone M., 2015, AUTOIMMUNE DIS PATHO
  • [6] Blanco AN, 1997, THROMB HAEMOSTASIS, V77, P656
  • [7] Blanco AN, 2002, HAEMATOLOGICA, V87, P271
  • [8] BRAY GL, 1994, BLOOD, V83, P2428
  • [9] CLIFFORD BD, 1995, HEPATOLOGY, V21, P613, DOI 10.1016/0270-9139(95)90507-3
  • [10] New associations: INFG and TGFB1 genes and the inhibitor development in severe haemophilia A
    De Alencar, J. B.
    Macedo, L. C.
    De Barros, M. F.
    Rodrigues, C.
    Shinzato, A. H.
    Pelissari, C. B.
    Machado, J.
    Sell, A. M.
    Visentainer, J. E. L.
    [J]. HAEMOPHILIA, 2015, 21 (04) : E312 - E316